A five-year trial of the weight loss drug tirzepatide in Greater Manchester was announced last October ...

In this trial, both drugs helped improve these health markers, but tirzepatide’s added benefits could make it the top choice for many people with obesity. Still, not every patient will need the ...

Lilly’s Zepbound ® (tirzepatide) superior to Wegovy ® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs 13.7%. News release. Eli Lilly and Company.

Called tirzepatide, the drug helped overweight and obese participants lose up to 22.5 percent of their total body weight over the 72-week trial. SUBSCRIBE LOG IN ...

More than one-third of adults receiving tirzepatide in clinical trials experience gastrointestinal adverse events, but adverse events leading to drug discontinuation were rare, according to study ...

The 'twincretin' tirzepatide (Mounjaro) met its primary endpoints compared with placebo in the SURMOUNT-2 trial, designed to test weight loss efficacy, in top-line results reported by Lilly.

Researchers collected data from the five SURPASS trials, which assessed the effects of tirzepatide among people with type 2 diabetes. Tirzepatide was compared with placebo in SURPASS-1 and SURPASS ...

Lilly’s Zepbound (tirzepatide) superior to Wegovy (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs 13.7%. News release. Lilly; December 4, 2024.

Two more phase 3 clinical trials of Eli Lilly’s tirzepatide in Type 2 diabetics have met their primary endpoints. The studies, like a trial that read out late last year, linked the dual GIP/GLP ...

Top-line results from another two tirzepatide (Mounjaro) weight-loss pivotal trials in adults without diabetes pad the agent's sizeable evidence base and presage likely FDA approval later in 2023.

Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight and keep it off. First head-to-head trial compares tirzepatide and semaglutide - Results are in ...